

To: TB Community Groups and other interested parties

c/o Erica Lessem, MPH
Assistant Director, TB/HIV Project
Treatment Action Group
261 Fifth Avenue, Suite 2110
New York, NY 10016 USA

[See additional CC list at end of letter]

17 September 2014

Response to September 10 *Open letter*

Dear TB Community Groups and other interested parties,

Thank you for your letter dated September 10, 2014.

Janssen is committed to responsible *stewardship* of bedaquiline and ensuring it is appropriately used today to protect tomorrow's patient. This responsibility is the foundation of our clinical development, our pricing and access structure, and our public and private collaborations.

Our commitment extends to responsible distribution that ensures bedaquiline is made available through national TB Programs. We are not pursuing models that seek to expand utilization in self-pay or private sector channels that operate autonomously from national governments.

Janssen also is committed to the capture of real world evidence through a global disease registry that seeks to supplement data generated on the safety and efficacy of bedaquiline in clinical trials. The timely capture of this data will provide the basis for an expansion of current treatment guidelines.

Finally, Janssen is open to discussions about future access and financing models that lead to responsible treatment of more patients when conditions permit broader access to bedaquiline.

We welcome the opportunity to meet about our shared interests on September 24 and discuss the points raised in your letter, as well as how we can work together on the responsible stewardship of bedaquiline. We thank you for your engagement and that of all signatories, in an effort to accelerate the responsible capture of data and, following that, discussions aimed at designing access and financing models that provide lower cost treatment regimens.

Sincerely,



Myriam Haxaire –Theeuwes, Compound Development Team Leader, bedaquiline

Cc: Paul Stoffels, M.D., Worldwide Chairman, Pharmaceuticals and Chief Scientific Officer
Ross Underwood, Global Access Leader, Global Public Health
Chrispin Kambili, Global Medical Affairs Leader, Global Public Health
Tine de Marez, Program Management Officer, Global Public Health
On behalf of Janssen Pharmaceutical Companies of Johnson & Johnson